young TIL (NCT02621021)

Name: young TIL trial for Melanoma (NCT02621021)
Uploaded: 2026-10-31T21:48:46.285Z
Duration: 1 min 27 s
Description: young TIL trial for Melanoma (NCT02621021). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02621021.

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab: a one-minute explainerNCT026210211 min

young TIL trial for Melanoma (NCT02621021). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults aged 18–72 with metastatic skin melanoma resistant to PD-1/PD-L1 treatment. A removable tumor lesion is needed to grow immune cells.

The idea: tumor-infiltrating lymphocytes are collected, grown, and returned by infusion after cyclophosphamide/fludarabine conditioning. High-dose IL-2 supports the cell treatment. The current group receives pembrolizumab unless contraindications prevent it. Earlier groups are closed; current assignment is not randomized. Treatment requires hospitalization, tumor collection, and leukapheresis. Researchers measure tumor responses.

This phase 2 study plans 53 patients. Stephanie Goff leads at NCI in Bethesda, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.